WASHINGTON, DC –Today, President Trump signed two bills into law, the National Defense Authorization Act (NDAA) Conference Report and HR. 4374, legislation to address a provision within the NDAA.
Specifically, H.R. 4374 amends the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes. H.R. 4374 addresses language within the NDAA that would have undermined the U.S. Food and Drug Administration (FDA).
“This is an important day for our brave men and women in uniform, ensuring they get the timely care they need while protecting our country,” said Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX). “We commend all those at the committee and agency levels who came together to find a constructive compromise on an issue we all cared deeply about. Thanks to everyone’s willingness to have open, honest discussions, we were able to address a provision within the NDAA Conference Report that could have usurped FDA’s vital authority and long-standing process in reviewing and delivering cutting edge medicines and devices. Today we are well on our way to delivering the newest treatments and devices to our war fighters without forgoing important safety mechanisms.”